NASDAQ:FONR

FONAR (FONR) Stock Forecast, Price & News

$17.66

-0.10 (-0.56%)

(As of 06/9/2023 ET)

Compare

Today's Range: $17.50
▼
$17.80
50-Day Range: $15.27
▼
$17.76
52-Week Range: $13.28
▼
$19.00

Volume: 6,711 shs
Average Volume: 9,346 shs
Market Capitalization: $115.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About FONAR (NASDAQ:FONR) Stock

FONAR Corp. engages in the design, manufacture, sale, and servicing of magnetic resonance imaging scanners. It operates through the Manufacturing and Servicing of Medical Equipment and Management of Diagnostic Imaging Center segments. The Manufacturing and Servicing of Medical Equipment segment promotes its product, Fonar Upright MRI. The Management of Diagnostic Imaging Center segment offers management, administrative, billing and collection services, office space, equipment, repair, maintenance service and clerical, and non-medical personnel to medical providers through its subsidiary, Health Management Corp. of America. The company was founded by Raymond V. Damadian on July 17, 1978 and is headquartered in Melville, NY.

Receive FONR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FONAR and its competitors with MarketBeat's FREE daily newsletter.

FONR Stock News Headlines

June 10, 2023 | americanbankingnews.com

Analyzing Positron (OTCMKTS:POSC) and FONAR (NASDAQ:FONR)

June 7, 2023 | finance.yahoo.com

FONAR Corporation's (NASDAQ:FONR) top owners are retail investors with 49% stake, while 46% is held by institutions

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 23, 2023 | americanbankingnews.com

FONAR (NASDAQ:FONR) Lifted to "Strong-Buy" at StockNews.com

May 15, 2023 | finanznachrichten.de

Fonar Corporation: Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

May 15, 2023 | finance.yahoo.com

Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

May 13, 2023 | americanbankingnews.com

StockNews.com Downgrades FONAR (NASDAQ:FONR) to Buy

April 23, 2023 | finance.yahoo.com

Investors in FONAR (NASDAQ:FONR) have unfortunately lost 43% over the last five years

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

March 28, 2023 | finance.yahoo.com

Great news for FONAR Corporation (NASDAQ:FONR): Insiders acquired stock in large numbers last year

March 22, 2023 | americanbankingnews.com

FONAR (NASDAQ:FONR) vs. CONMED (NASDAQ:CNMD) Critical Comparison

February 5, 2023 | finance.yahoo.com

FONAR (NASDAQ:FONR) Could Be Struggling To Allocate Capital

December 29, 2022 | finance.yahoo.com

While institutions own 39% of FONAR Corporation (NASDAQ:FONR), individual investors are its largest shareholders with 50% ownership

November 30, 2022 | finance.yahoo.com

Fonar Corporation Designates Laurel Hill Advisory Group, LLC as Information Agent for the Company's $9 Million Share Repurchase Program

November 17, 2022 | finance.yahoo.com

FONAR Reports First Quarter 2023 Earnings

November 14, 2022 | finance.yahoo.com

Investors in FONAR (NASDAQ:FONR) have unfortunately lost 23% over the last five years

October 25, 2022 | nasdaq.com

Fonar Corporation Common Stock (FONR)

October 24, 2022 | reuters.com

FONR.A - Fonar Corporation | Stock Price & Latest News | Reuters

October 19, 2022 | finance.yahoo.com

Quite a few insiders invested in FONAR Corporation (NASDAQ:FONR) last year which is positive news for shareholders

October 17, 2022 | streetinsider.com

Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients - StreetInsider.com

October 17, 2022 | streetinsider.com

Statera Biopharma (STAB) Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients - StreetInsider.com

October 13, 2022 | globenewswire.com

Global MR Imaging in Neurosurgery Market Analysis Report 2021-2031: Opportunities in the Development of Cost-Effective Robotic-Assisted MRI Systems and MRI-Compatible Robotic Systems - GlobeNewswire

October 7, 2022 | benzinga.com

MRI System Market Expected to Increase 1.7x During 2022-2030 | Soaring Prevalence of Chronic Diseases Pri - Benzinga

October 6, 2022 | nasdaq.com

A Look At The Intrinsic Value Of FONAR Corporation (NASDAQ:FONR) - Nasdaq

October 6, 2022 | nasdaq.com

A Look At The Intrinsic Value Of FONAR Corporation (NASDAQ:FONR)

October 5, 2022 | finance.yahoo.com

Estimating The Fair Value Of FONAR Corporation (NASDAQ:FONR)

September 28, 2022 | marketscreener.com

FONAR CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION. (form 10-K) - Marketscreener.com

See More Headlines

FONR Price History

30 days | 90 days | 365 days | Advanced Chart

FONR Company Calendar

Last Earnings: 5/11/2020
Today: 6/10/2023
Fiscal Year End: 6/30/2023
Next Earnings (Estimated): 8/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FONR
CUSIP: N/A
CIK: 355019
Web: www.fonar.com
Phone: (631) 694-2929
Fax: 631-753-5150
Employees: 495
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $12.44 million
Net Margins: 10.63%
Pretax Margin: 17.11%
Return on Equity: 7.97%
Return on Assets: 5.94%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 8.76
Quick Ratio: 8.57

Sales & Book Value

Annual Sales: $97.59 million
Price / Sales: 1.18
Cash Flow: $3.91 per share
Price / Cash Flow: 4.52
Book Value: $22.31 per share
Price / Book: 0.79

Miscellaneous

Outstanding Shares: 6,540,000
Free Float: 5,977,000
Market Cap: $115.50 million
Optionable: Not Optionable
Beta: 0.91

Key Executives

Timothy R. Damadian
Chairman, President & Chief Executive Officer

Luciano Bonanni
Chief Operating Officer & Executive Vice President

Claudette J. V. Chan
Secretary & Director

Daniel Culver
Communications Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FONR Stock - Frequently Asked Questions

How have FONR shares performed in 2023?: FONAR's stock was trading at $16.75 at the beginning of 2023. Since then, FONR shares have increased by 5.4% and is now trading at $17.66.
View the best growth stocks for 2023 here.
When is FONAR's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our FONR earnings forecast.
How were FONAR's earnings last quarter?: FONAR Co. (NASDAQ:FONR) posted its earnings results on Monday, May, 11th. The medical equipment provider reported $0.18 earnings per share for the quarter. The medical equipment provider earned $21.69 million during the quarter. FONAR had a net margin of 10.63% and a trailing twelve-month return on equity of 7.97%.
What other stocks do shareholders of FONAR own?: Based on aggregate information from My MarketBeat watchlists, some companies that other FONAR investors own include Gilead Sciences (GILD), Amarin (AMRN), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Pfizer (PFE), Bausch Health Companies (BHC), Incyte (INCY), Jazz Pharmaceuticals (JAZZ), Lannett (LCI) and Madrigal Pharmaceuticals (MDGL).
What is FONAR's stock symbol?: FONAR trades on the NASDAQ under the ticker symbol "FONR."

Who are FONAR's major shareholders?: FONAR's stock is owned by many different retail and institutional investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (9.69%), Dimensional Fund Advisors LP (6.24%), Renaissance Technologies LLC (5.03%), Money Concepts Capital Corp (4.63%), LSV Asset Management (2.24%) and BlackRock Inc. (1.51%). Insiders that own company stock include Luciano B Bonanni and Timothy Raymond Damadian.
View institutional ownership trends.
How do I buy shares of FONAR?: Shares of FONR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is FONAR's stock price today?: One share of FONR stock can currently be purchased for approximately $17.66.
How much money does FONAR make?: FONAR (NASDAQ:FONR) has a market capitalization of $115.50 million and generates $97.59 million in revenue each year.
How many employees does FONAR have?: The company employs 495 workers across the globe.
How can I contact FONAR?: FONAR's mailing address is 110 Marcus Drive, Melville NY, 11747. The official website for the company is www.fonar.com. The medical equipment provider can be reached via phone at (631) 694-2929, via email at investor@fonar.com, or via fax at 631-753-5150.

This page (NASDAQ:FONR) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial